Revenue

As Par Pacific prepares its Q2 results, investors will scrutinize how it balanced geopolitical oil price spikes with the pivotal launch of its Hawaii renewables plant.

As HESM preps its Q2 earnings call, the market is watching. Beyond the numbers, it's a test of its fee-based model against Bakken's pulse.

As Hubbell readies its Q2 results, all eyes are on its ability to power the AI boom and grid upgrades. We look beyond the numbers at the strategy behind the surge.

Amid record production and surging drilling, PrairieSky's results showcase its resilient royalty model and signal renewed investment vigor in Canada's oil patch.

Astrana Health is betting big on two veteran executives to scale its AI-driven model. This move isn't just about growth—it's about execution in a booming market.

The German biotech has slashed its revenue forecast and now projects a major loss, sending a shockwave through the market and raising questions about its health.

A dividend announcement from Bluerock Homes Trust reveals more than just returns; it exposes the sophisticated financial networks funding housing in America's tech hubs.

Photonics leader Coherent's spot on TIME's Best Companies list isn't just about profits. It's a story of culture, sustainability, and strategic focus.

As Alberta opens its billion-dollar iGaming market, global giant bet365 joins a crowded field. Can its unique features and CFL pact conquer the West?

With a new CMO, $50M in fresh capital, and pivotal trials on the horizon, Cue Biopharma makes a strategic bet on an immunology veteran to guide its future.

As solar tracker giant Array Technologies preps its Q2 results, we look beyond the numbers at the market forces and strategic shifts defining the industry.

McDermott Will & Schulte's hire of a top PE lawyer isn't just a personnel move. It's the capstone of a decade-long strategy to conquer New York.

Ocugen inks a potential $255M+ deal to bring its OCU400 gene therapy for Retinitis Pigmentosa to the MENA region, a strategic move into a high-need market.

Delonix Bioworks is running parallel trials in China and Australia for its MenB vaccine, a strategic gambit that could disrupt a billion-dollar market.

Fresh from a 2020 bankruptcy, the menswear giant behind Men's Wearhouse is going public. Can it convince Wall Street that suits and stores have a future?

A seven-year contract extension is more than a renewal; it’s a strategic play. We analyze why Brightstar is doubling down on lottery tech in Washington.

Webuy's new AI Smart Travel Card aims to unify the travel journey. Is this a game-changing strategic move or a risky gamble in a competitive market?

Gentoo Media's appointment of Måns Svalborn signals a clear intent to accelerate its M&A strategy in a consolidating iGaming affiliate market.

YSX Tech reports a 17% revenue jump but a 30% profit drop, a deliberate move to dominate China's insurance market. Is this a winning long-term play?

As Silgan prepares its Q2 2026 report, we look beyond the numbers at a company navigating sustainability demands and economic shifts. What can it tell us?